The inherently low regenerative capacity of the CNS demands effective strategies to inhibit neurodegeneration in acute lesions but also in slowly progressive neurological disorders. Therefore, therapeutic targets that can interact with the degeneration cascade to block, not just postpone, neuronal degeneration need to be defined. Bcl-X L , a protein protecting the integrity of the mitochondrial membrane potential, was investigated for its neuroprotective properties in a longterm in vivo model of neuronal cell death. An AAV-2-based vector was used to express both Bcl-X L and EGFP in retinal ganglion cells (RGCs) of the adult rat retina. Transection of the optic nerve results in degeneration of RGCs in control retinae, while Bcl-X L -overexpressing ganglion cells were protected from degeneration. At 2 weeks after axotomy, 94% of the transduced RGCs survived the lesion (15% in controls). For the first time, we investigated RGC survival up to 8 weeks after axotomy and detected that 46% of the Bcl-X L -overexpressing RGCs still survived, representing significantly increased neuroprotection compared to neurotrophin-based approaches. We could also show that the axons of AAV-Bcl-X L -transduced RGCs remained morphologically intact after the lesion, thus providing the basis for regeneration-inducing attempts.
INTRODUCTION
Neither in acute lesions (trauma, ischemia) nor in slowly progressive neurodegenerative diseases (Alzheimer and Parkinson disease, amyotrophic lateral sclerosis) can severed and subsequently degenerating neurons be replaced endogenously due to the inherently low regenerating capacity of the CNS. Therefore it is of the highest clinical interest to minimize neuronal cell loss to preserve as many functional circuits as possible. Probably the most important role in the decision whether an adult neuron dies or survives is played by the mitochondria [1, 2] . These organelles provide the cell's energy by oxidative phosphorylation and may serve as Ca 2+ buffers, but are also the main cellular source of reactive oxygen species. They harbor proteins essential for the progression of apoptotic cell death, such as AIF (apoptosis inducing factor), smac/ Diablo, and cytochrome c, which are released from mitochondria upon loss of outer membrane potential [3] [4] [5] [6] [7] [8] . It is this detrimental loss of mitochondrial membrane potential that is thought to be the bpoint of no return,Q ultimately leading to cell death even if the degeneration-inducing stimulus is withdrawn [9] [10] [11] . Cytochrome c together with caspase 9 and Apaf1 forms the apoptosome (the protein complex necessary for caspase 9 activation) and thereby initiates the caspase cascade, while AIF may induce a non-caspase-dependent cellular destruction [7] .
The proteins of the Bcl-2 family are important mediators of mitochondrial integrity. Antiapoptotic members of the Bcl-2 protein family (Bcl-X L , Bcl-2) are expressed at high levels in the CNS at early developmental stages. In the adult CNS, Bcl-2 levels are drastically reduced, while several brain structures still express detectable amounts of Bcl-X L [12] [13] [14] . Bcl-2 and Bcl-X L sequester the bBH3 domainQ family members (e.g., Bid, Bad, Bik, Bim), which serve as sensors for several proapoptotic stimuli (e.g., Ca 2+ overload, elevated levels of reactive oxygen species, or activation of membranebound receptors). This sequestration prevents activation and oligomerization of the bmultidomainQ family members Bax and Bak, which otherwise induce outer mitochondrial membrane potential breakdown and subsequent apoptosis [15] .
In an attempt to define therapeutic targets for the sustained inhibition of neurodegeneration we aimed to investigate whether stabilization of mitochondrial integrity may prevent, not just delay, neurodegenera-tion. As a test system we have used an established traumatic lesion model: axotomy of the optic nerve leads to apoptotic degeneration of retinal ganglion cells (RGCs), with 85-90% of these neurons dying within 10-14 days after the lesion [16] [17] [18] , a process shown to be associated with mitochondrial cytochrome c release [8] . We have used an adeno-associated virus (AAV-2)-based vector to overexpress Bcl-X L in adult RGCs in a defined area of the affected retinal tissue. We found long-term surviving RGCs only in the AAV-Bcl-X Ltransduced area of the retinae, with 94 and 46% surviving RGCs at 2 and 8 weeks after axotomy, respectively. Thus, preserving mitochondrial function appears to be a well suited approach to the sustained inhibition of neurodegeneration.
RESULTS

Transduction of RGCS by Bicistronic AAV-2 Vectors
To express both Bcl-X L and the reporter EGFP from a single recombinant AAV-2 vector, we have made use of small transcriptional control elements that allow us to overcome the AAV-inherent limitations in transgene capacity. The genomes of the two vectors used in this study are schematically depicted in Fig. 1A . While AAVBcl-X L expressed Bcl-X L and EGFP from two independent synapsin-1 gene promoters, AAV-EGFP expressed EGFP from a synapsin promoter but contained a disabled Bcl-X L expression cassette. We confirmed protein expression from the vectors in cultured hippocampal neurons. Fig. 1B shows that both vectors expressed equal amounts of EGFP, but only AAV-Bcl-X L expressed the Bcl-X L transgene, while no Bcl-X L expression above endogenous levels was detected from the AAV-EGFP vector.
In preliminary experiments we determined the viral titer necessary for partial transduction of the rat retina. Titers of 10 8 transducing units resulted in transduction of most of the retinal area; however, the efficacy varied depending on the distance from the injection site. Titers of 10 7 transducing units resulted in a limited but more homogeneous transduction and were used throughout the experiments ( Figs. 2A and 2B ). In the center of the transduced area transduction efficacy was determined by comparing EGFP fluorescence with the RGC tracer FluoroGold (FG), which was retrogradely applied at the cut optic nerve stump. We found that 90 F 5% of the FGlabeled RGCs were transduced by the AAV-2 vectors as revealed by EGFP-FG colocalization (Figs. 2C and 2D ). In these specimens at least 50-60% of the retinal area was completely negative for any EGFP expression. These untransduced areas could serve as negative controls for RGC survival using the same retinal specimens as for the determination of survival due to Bcl-X L expression. Furthermore, limited transduction allowed for the unambiguous identification of dendritic and axonal projections originating from transduced RGCs (Figs. 2A, 4B , 4D, and 6).
Expression kinetics driven by the human synapsin-1 gene promoter were divergent in the transduced retinal neurons (Figs. 2E and 2F): (i) the rare large class I RGCs expressed very high levels of EGFP, (ii) the transduced amacrine cells (roughly 5% of the amacrine neurons, which make up about 40% of the neurons in the RGC layer, were transduced) also express high levels of EGFP, and (iii) the majority of the predominant small class II RGCs showed predominantly moderate EGFP fluorescence (for details of RGC types see [19] ). We found these expression characteristics irrespective of the time point after vector application and in both axotomized and control retinae. Influences of axotomy on transgene expression were not detectable, since the same EGFP expression characteristics were also obtained in animals that had received the FG label by stereotaxic injection into the superior colliculi (these animals were not subjected to axotomy, data not shown).
We confirmed RGC-specific transduction on retinal sections, showing that the vast majority of EGFP-expressing cells were concomitantly labeled with the RGCspecific FG (Figs. 3A-3C ). Bcl-X L expression in RGCs was confirmed by immunohistochemistry. Almost all EGFP-expressing RGCs were also stained by a Bcl-X antibody (Figs. 3D-3F ). Barely any staining for Bcl-X L was detected in either AAV-EGFP-transduced or nontransduced retinal areas (Fig. 3G) . While EGFP fluorescence in individual cells was distributed uniformly all over the cytoplasm (Fig. 3H) , Bcl-X L expression was localized to granule-like structures in the cytoplasm, sometimes extending into larger neurite structures (Fig.  3K) , suggesting mainly mitochondrial localization. In contrast to EGFP fluorescence, which labels dendritic as well as axonal structures of the transduced RGCs almost completely (Figs. 3B and 3L), Bcl-X L expression was rarely detected in dendritic structures and appeared to be absent or below the detection limit in axons projecting toward the optic disc (Fig. 3M) .
Quantitative Rescue from Axotomy-Induced Neurodegeneration by Bcl-X L at 2 Weeks after Axotomy Counting fluorescently labeled RGCs after axotomy of the optic nerve is a commonly used model system in neurodegeneration and neuroprotection research. Since 85-90% of the deafferented RGCs have undergone degeneration at 10-14 days after the lesion, the point of time 14 days postlesion is usually used to determine whether neuroprotective strategies are successful in this model. When we counted surviving RGCs (for details see next section and Fig. 4 ) in the AAV-Bcl-X L -transduced retinal areas at 14 days after axotomy, we found RGC numbers very similar to those of unlesioned controls. In unlesioned control retinae RGC numbers of 2200 F 80/ mm 2 were counted at 2/3 retinal radius, of which 90% (1980 F 110) were transduced by the vectors as judged by EGFP/FG colocalization (n = 4). At 2 weeks after axotomy, we counted 1870 F 150 RGC/mm 2 in the AAV-Bcl-X Ltransduced retinal area (n = 4), representing 94.4% of the transduced RGCs (Fig. 5 ). In the retinal areas outside vector transduction only 319 F 10 RGC/mm 2 survived at that point of time (representing 15% of all RGCs, n = 4). We detected comparably low numbers of surviving RGCs in AAV-EGFP-transduced retinal areas (n = 4). Despite substantial loss of RGCs, these areas could easily be identified by EGFP expression in amacrine cells and in the residual surviving RGCs (mainly of the large class I, expressing high levels of EGFP). No significant differences in RGC numbers were found either in retinal areas that were not transduced after AAV-Bcl-X L application or in transduced or nontransduced areas after AAV-EGFP application. Thus, no effect of the vector application itself on RGC survival was detected. This finding allowed for utilization of the untransduced retinal areas after AAV-Bcl-X L transduction as proper controls for cell survival. Taken together, RGC numbers determined at 2 weeks after the lesion revealed that Bcl-X L overexpression rescued RGCs nearly quantitatively from axotomyinduced neurodegeneration.
Bcl-X L Mediates Efficient Long-Term Protection from Axotomy-Induced Neurodegeneration
To determine whether Bcl-X L overexpression may have longer lasting protective effects we also determined RGC Analysis of the FG labeling pattern after axotomy in either untransduced or AAV-EGFP-transduced retinal areas revealed that the vast majority of FG-labeled cells were microglial cells. Only a few cells identified as RGCs could be detected in these specimens. Despite this pronounced degeneration of RGCs the dendritic network originating from the surviving neurons apparently remained intact, as demonstrated by EGFP-labeled neurites present in the nontransduced areas of the retinae (Fig. 4B, left) . Thus, phagocytosis of apoptotic RGCs by microglial cells is clearly a highly specific process not affecting other, nonapoptotic, neuronal structures.
In the AAV-Bcl-X L -transduced areas of the retinae we detected mainly RGCs at 4 weeks after axotomy, while only very few FG-labeled cells were of microglial morphology (Fig. 4C) . Coincident with this profound neuroprotection of RGC cell bodies we detected a dense network of fibers spread all over the retinae, indicating that dendritic trees of the surviving RGC are also protected (Fig. 4D, left) . In the nontransduced areas of the same retinae we could not detect any neuroprotection, as clearly demonstrated by an FG-labeling pattern identical to AAV-EGFP-transduced retinae: only very few cells showed the perinuclear, punctate FG labeling pattern, while most FG-labeled cells were of microglial morphology (Fig. 4D, right) . At 4 weeks after axotomy we identified 1441 F 14 RGCs/mm 2 in AAV-Bcl-X L -transduced retinae (Fig. 4C) . At 6 and 8 weeks after axotomy, we counted 1320 F 90 and 912 F 98 RGCs/mm 2 in AAV-Bcl-X L -transduced retinal areas, respectively. AAV-Bcl-X L transduction thus resulted in the protection of 73% axotomized and transduced RGCs at 4 weeks after lesion (10% in controls), 67% at 6 weeks after lesion (11% in controls), and 46% at 8 weeks after lesion (6% in controls) (Fig. 5) .
Bcl-X L Overexpression Preserves Axonal Morphology EGFP expressed from the AAV vectors resulted in an apparently complete labeling of dendrites, cell bodies, and axons of the transduced RGCs. This allowed for a morphological estimation as to whether surviving RGCs could preserve their axonal structures up to the lesion site, providing the basis for regeneration-inducing attempts. Since we have used a limited transduction of the retina, axon fascicles could easily be observed projecting from the transduced area to the optic disc. These axon fascicles, originating from surviving RGCs, were preserved throughout the course of the experiment. In whole-mounted retinae we detected a density of EGFPlabeled fascicles roughly proportional to the RGC cell counts obtained, that is, we observed some reduction in fascicle density over time (compare Figs. 6A and 6B) . However, since the exact intraretinal determination of axon numbers in whole mounts is difficult due to the fasciculation, this observation has to be taken as semiquantitative only.
Axon fascicles in control retina (no axotomy) examined at 9 weeks after AAV-Bcl-X L transduction showed regular and straight shape, including several distinct varicosities (Fig. 6C) . In retinae examined at 2 weeks after axotomy, axonal morphology was very similar to that of the controls, with straight fascicles and clearly detectable varicosities (Fig. 6D) . At 6 weeks after axotomy, axon morphology appeared somewhat disturbed: fascicles often displayed a frayed shape and the number of varicosities was clearly reduced (Fig. 6E) . Nonetheless, labeled axons were protruding to the very end of the proximal optic nerve stump for up to 8 weeks after axotomy without showing detectable retraction (not shown).
DISCUSSION
Recent work on the molecular mechanisms leading to neurodegeneration in the adult CNS revealed common principles: rapid necrotic cell death occurs as a consequence of excitotoxicity and complete mitochondrial energy depletion (e.g., in the infarct core region), while delayed degeneration of neurons follows mainly the apoptotic pathway [20] . Aberrant cell death activation in the adult CNS is implicated in many neurodegenerative diseases, although it is still controversial which parts of the cell death cascades are actually activated in certain diseases and to what extent they finally contribute to neurodegeneration [21] [22] [23] . Transection of the optic nerve and the subsequent apoptotic degeneration of 85-90% of retinal ganglion cells within 10-14 days constitutes a highly reproducible model system of neurodegeneration in the adult CNS, which allows us to study neurodegenerative, -protective, and -regenerative mechanisms [24] [25] [26] .
Although cell replacement strategies may become applicable in the future, ethical and technical problems still limit their use considerably [27] [28] [29] . Thus, it is obvious that protection of adult neurons from degeneration is a fundamental requisite for restorative therapies. Since many proapoptotic stimuli converge on the mitochondria, these organelles play a key role in the decision of cell fate, making them important therapeutic targets. Here we have demonstrated for the first time that gene transfer of a protein that has been shown to stabilize mitochondrial integrity by sequestering the BH3-only proteins can prevent degeneration of deafferented adult CNS neurons over extended periods of time. Our data suggest that preserving mitochondrial function is a critical step in neuroprotection at least after traumatic CNS lesion. Since Bcl-X L gene transfer has been shown to be neuroprotective in cultured cerebellar granule neurons upon serum/potassium withdrawal [30] , in a short-term middle cerebral artery occlusion model of stroke [31] , and 
FIG. 6. Preservation of proximal axons after axotomy of
Bcl-X L -expressing RGCs. Flat-mounted retinae transduced with AAV-Bcl-X L (A) without axotomy or (B) at 6 weeks after axotomy are shown as overlays of EGFP reporter gene fluorescence with the phase-contrast image of retinal tissue. Axon bundles emanating from the transduced area are clearly visualized due to their EGFP fluorescence. Higher magnification pictures of axon bundles at (C) 9 weeks after transduction (without axotomy), serving as controls, (D) 2 weeks after axotomy, and (E) 6 weeks after axotomy show that gross axonal morphology is preserved at 2 weeks after axotomy but appears distorted at 6 weeks after axotomy. Arrows point to varicosities clearly visible in controls and at 2 weeks after axotomy but only very rarely at 6 weeks after axotomy. Scale bar, 500 Am in (A) and (B) and 55 Am in (C-E).
in cholinergic neurons after fimbria fornix lesion [32] , accumulating evidence defines this protein as a valuable therapeutic target for neuroprotection strategies. Longterm studies aiming to investigate the protective function of Bcl-X L in other experimental lesion paradigms should now clarify whether this protein has ubiquitously utilizable neuroprotective properties. This task will be substantially facilitated by the employment of a viral vector system as described in this study, which allows for longterm transgene expression in the CNS without obvious side effects and which clearly demarcates transduced cells by the additional incorporation of a fluorescent reporter gene.
Neurons surviving the maturation of the nervous system are protected from degeneration of more than 50% of the neuronal precursors by trophic support of neurotrophins but also by elevated levels of intracellular proteins of, e.g., the Bcl-2 family [20] . Thus, recapitulating these early protective mechanisms in the treatment of neurodegenerative diseases may be a successful neuroprotective strategy. Mechanistically, this could be approached by two different ways: (i) secreted neurotrophic factors are synthesized by either neurons or glial cells and after secretion act through their respective receptors to promote neuroprotection or (ii) intracellular proteins mediating neuroprotective effects are overexpressed in the affected neuronal populations. The neurotrophin approach may generally be considered to be more promising due to the secretion and potentially more widespread distribution of the protection-inducing molecule. However, the use of neurotrophins in the optic nerve axotomy model has so far mediated only shortterm protection. The sophisticated approach using RGCspecific overexpression of the BDNF receptor trkB in combination with intravitreal injection of recombinant BDNF [33] or the lentivirus-mediated overexpression of CNTF [34] resulted in comparable survival rates of RGCs at 2 weeks after axotomy compared to Bcl-X L overexpression (BDNF + trkB, 1732 RGC/mm 2 ; CNTF, 1673 RGC/mm 2 ; Bcl-X L , 1870 RGC/mm 2 ), but showed a pronounced decline in RGC numbers already at 3 or 4 weeks after axotomy (4 weeks BDNF + trkB, 378 RGC/ mm 2 ; 3 weeks CNTF, 755 RGC/mm 2 ; 4 weeks Bcl-X L , 1441 RGC/mm 2 ). These results strikingly emphasize the need for longer term studies on neuronal survival to define the most effective means of counteracting neurodegeneration. To our knowledge, the study presented here represents the longest period of time evaluated after neuroprotective gene transfer.
Longer term studies on the protection of RGCs after axotomy have so far been done only in mice constitutively overexpressing Bcl-2. However, these animals display RGC numbers highly exceeding those of normal littermates, since developmental neurodegeneration necessary for the elimination of excess RGCs is impaired [35] . After axotomy these mice display 63% of surviving RGCs at 2-3 months after the lesion [36] . This value is similar to the 46% of surviving RGCs after AAV-Bcl-X L transduction at 2 months after lesion. Thus, AAV-2 vector-mediated btransgenesisQ appeared to be a suitable alternative for the transgenic mouse model. The vector-based approach circumvents any compensatory events that might have occurred in the transgenic mice during development [37] and can be used for a spatially and temporally controlled transgene expression. This allowed us to evaluate RGC survival in a degenerating environment (which is represented by the nontransduced parts of the retina), showing that despite ongoing degeneration and microglial activation in the nontransduced area the dendritic trees of the Bcl-X L -expressing RGCs were maintained. The incorporation of a fluorescent reporter gene into the viral vector genome furthermore allowed for direct labeling of the axons of surviving RGCs. Thereby we were able to demonstrate that Bcl-X L preserved not only the cell bodies but also the proximal parts of the axons, thus providing the structural basis for axonal regeneration. A combination of survival-promoting therapy as demonstrated here together with targeting nogo-receptor signaling to interfere with inhibitory signals from the repulsive CNS environment [38] may ultimately lead to sophisticated axonal regeneration of RGCs.
Despite effective and sustained RGC rescue by Bcl-X L overexpression there was still a significant decline in RGC numbers over the course of the experiment. This might have been due to the following reasons. First, the promoter used to drive transgene expression from the AAV vector showed strong transgene expression in the rare large class I RGCs and the transduced amacrine neurons but was only moderately active in the majority of the predominant class II RGCs. Furthermore, in contrast to the EGFP reporter gene, the Bcl-X L expression cassette did not contain the WPRE, which substantially enhances protein expression [39] . The Bcl-X L expression levels achieved might not have been sufficient to maintain mitochondrial integrity in all transduced RGCs. The lack of detectable Bcl-X L expression in axonal varicosities, which harbor mitochondrial accumulations in the unmyelinated and metabolically active prelaminar parts of RGC axons [40] , strengthens this hypothesis. Second, it has been shown that axotomized RGCs depend on target-derived factors that enable them to survive and regenerate into permissive substrates such as a transplanted sciatic nerve [19] . Thus, the obvious morphological distortion in the axons of Bcl-X L -transduced RGCs observed at 6 weeks after the lesion may be either a direct result of a lack of tectum-borne trophic support or a more general result of impaired axonal transport mechanisms due to the deafferentation. While higher levels of Bcl-X L may compensate for these impacts, RGCs with lower Bcl-X L levels may ultimately degenerate.
In general, the efficient and selective transduction of RGCs by AAV-2-based vectors shown in this and other recent studies [33, 38, 41] not only enables investigations of the basic mechanisms of neuronal de-and regeneration, but also holds great promise for clinical applications. Since RGC degeneration is a hallmark of several diseases causing at least partial blindness (glaucoma, Leber inherited optic neuropathy, Kjer dominant optic atrophy [42] ) protection of these neurons by gene therapy may ultimately lead to effective therapeutic strategies.
MATERIALS AND METHODS
Viral vector construction. For construction of AAV-Bcl-X L the pTRUF-22 plasmid (gift from S. Zolothukin) was modified so that all elements in between the left inverted terminal repeat and the WPRE were removed and replaced by one expression cassette consisting of the human synapsin 1 (hSyn1) gene promoter (a 470-bp fragment of the proximal promoter; for details see [30, 43] ) and EGFP (WPRE and bovine growth hormone polyadenylation site of pTRUF-22 were used) and another expression cassette consisting of the hSyn1 promoter, the rat Bcl-X L cDNA, a small intron derived from pCI-neo, an SV40 polyadenylation site, and a synthetic transcription blocker, which is also derived from pCI-neo. The control vector AAV-EGFP was constructed by replacing the human synapsin promoter controlling Bcl-X L expression with an SV40 polyadenylation site and a synthetic transcription blocker. Vectors were propagated in 293 cells using the pDG helper [44] , thus excluding any adenoviral contamination. Viral particles were purified according to established protocols [45] by iodixanol step gradient centrifugation followed by heparin-affinity chromatography on an Ä KTA FPLC system using 1 ml HiTrap Heparin FF columns (Pharmacia) for further purification and concentration. FPLC-purified/concentrated vectors were desalted by dialysis against PBS. Genome titers were determined by quantitative PCR and purity was confirmed by PAGE. Genome titers obtained from 25 transfected 175-cm 2 cell culture flasks were 1.5 Â 10 12 particles/ml for both vectors. Typically, vector preparations contained a ratio of 1:30 transducing units versus total viral particles. Due to the neuron-specific expression characteristics of the synapsin promoter [30] functional titers of the vectors were confirmed by EGFP expression analysis in cultured hippocampal neurons, which were prepared essentially as described [46] . Lysates obtained from these neuronal cultures were used to confirm protein expression from the viral vectors by Western blotting.
Surgical procedures. Injection of AAV-2 vectors was performed by means of a fine glass microelectrode coupled to a Hamilton syringe. Each injection consisted of 2 Al containing 3 Â 10 8 AAV genomes (equivalent to 1 Â 10 7 transducing units). Vector injections were performed under general anesthesia (chloral hydrate, 340 mg/kg body wt, ip) 3 weeks before axotomy into female Wistar rats of 225-250 g body wt. Pupillary dilatation was achieved with 1% tropicamide and 2% mepivacaine. Using an operating microscope, 2 Al of the virus preparations were injected into the intravitreal space, puncturing the eyeball below the cornea-sclera junction by means of a glass microelectrode with a tip diameter of 30 Am. Due to pupillary dilatation, the tip could be visualized during insertion and care was taken to avoid any penetration of the lens. Unilateral axotomy of the optic nerve was performed essentially as described [24] . Rats were anesthetized with chloral hydrate (420 mg/kg body wt, ip). After skin incision close to the superior orbital rim, the orbita was opened taking care to leave the supraorbital vein intact. Following subtotal resection of the lacrimal gland, the superior extraocular muscles were spread by means of a small retractor. The optical nerve was exposed by longitudinal incision of the eye retractor muscle and the perineurium. Optic nerve transection was performed at a distance of approximate 2 mm from the posterior pole of the eye without damaging retinal blood supply. Animals with retinal ischemia as verified fundoscopically were excluded from the study. Labeling of RGCs by the retrograde tracer FG was done at the time of axotomy by placing a small sponge soaked with FG onto the proximal optic nerve stump. FG labeling efficacy in vector-transduced, axotomized retinae was undistinguishable from control, which had received FG injections into the superior colliculi.
Quantification of surviving RGC. At the respective time points after axotomy, eyes were removed from the animals after application of a lethal dose of chloral hydrate. Four animals each were used for quantification of RGC numbers in AAV-EGFP-and AAV-Bcl-X L -transduced retinae at 2 and 4 weeks after axotomy; retinae from four animals were investigated at 6 weeks after axotomy (AAV-Bcl-X L transduced only) and three retinae from AAV-Bcl-X L -transduced animals were counted at 8 weeks after axotomy. Eyes were fixed in 4% paraformaldehyde for 2 h, then the retinae were excised, flat mounted on object slides, and embedded in Mowiol. The vector-transduced area of the retina was identified by EGFP-expressing cells. In the center of the transduction area at 2/3 retinal radius counts of FG-labeled RGCs were performed in three nonoverlapping sites. Although a commercial FG narrow-band filter set was used, EGFP fluorescence from strongly labeled amacrine neurons showed some leakthrough into this filter at longer exposure times. Thus, only those cells displaying a round shape and punctate, perinuclear FG accumulations were counted as RGCs.
Immunohistochemistry. For preparation of retinal sections animals were intracardially perfused with PBS followed by 4% paraformaldehyde (PFA). The eyes were removed, postfixed for 2 h in 4% PFA, and enucleated. After being embedded in Cryomatrix 12-Am sections were cut on a cryostat, mounted onto object slides, and stored frozen. For immunohistochemistry, specimens were subjected to antigen retrieval, blocked in 10% goat serum, and incubated with the primary antibody (anti-Bcl-X; Transduction Laboratories; 1:500 in 2% goat serum) overnight at 48C and, after four washes in PBS, with the secondary Cy3-coupled antibody (Dianova). Fluorescence of sections and whole-mounted retinal specimens was observed and recorded on a Zeiss Axioplan 2 microscope equipped with a CCD camera and AxioVision 3 software (Zeiss).
Statistics. RGC counts are given as means F standard deviations of three individual counts per retina; three or four retinae were used for each time point. Statistical significance was assessed by split-plot analysis of variance and a-adjusting for multiplicity (Bonferroni-Holm sequentially rejective procedure) and, at the 1% level, revealed P b 0.001 for Bcl-X Ltransduced areas versus nontransduced and versus control vector-transduced areas at all time points investigated.
